No profile data available.
Corcept Therapeutics Incorporated (CORT) is a healthcare company in the additional hormone and metabolic drugs industry, based in Redwood City, United States, with about 730 full-time employees.
It reported revenue of $761.41 million for fiscal year 2025, up 12.8% from fiscal year 2024, and net income of $98.17 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $256.15 million, up 31.7% from a year before. Its market capitalization was $13.10 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Corcept Therapeutics reported $761.41 million in revenue for fiscal year 2025, up 12.8% from $675.04 million in fiscal year 2024. In Q2 2026 revenue was $256.15 million.
$13.10 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include Alnylam Pharmaceuticals, Inc. (ALNY), BridgeBio Pharma, Inc. (BBIO), Amylyx Pharmaceuticals, Inc. (AMLX), MBX Biosciences, Inc. (MBX).